Related Experiment Video
Updated: Aug 22, 2025
08:04
Analyzing Platelet Subpopulations by Multi-color Flow Cytometry
Published on: June 10, 2025
300
Plasmalogens and platelet-activating factor roles in chronic inflammatory diseases
Marie-Ève Tremblay1,2,3,4,5,6, Zakaria A Almsherqi7, Yuru Deng8
1Division of Medical Sciences, University of Victoria, Victoria, British Columbia, Canada.
Biofactors (Oxford, England)
|November 12, 2022
Summary
Plasmalogens are vital ether phospholipids. Declining plasmalogen levels and excess platelet-activating factor (PAF) are linked to chronic inflammation, suggesting plasmalogen replacement therapy as a potential treatment.
Area of Science:
- Biochemistry
- Cell Biology
- Immunology
Background:
- Ether phospholipids, including platelet-activating factor (PAF) and its precursor plasmalogen, are crucial for cell membrane structure and function.
- Chronic inflammatory, neurodegenerative, and metabolic disorders are often associated with altered levels of PAF and plasmalogens.
- The precise molecular mechanisms of plasmalogen involvement in inflammation remain under investigation.
Purpose of the Study:
- To review the emerging roles of plasmalogens in chronic inflammatory disorders.
- To explore the therapeutic potential of plasmalogen replacement therapy for PAF-related pathologies.
Main Methods:
- Literature review focusing on plasmalogen biochemistry and inflammatory pathways.
- Analysis of studies investigating the link between plasmalogens, PAF, and chronic diseases.
- Evaluation of evidence for plasmalogen replacement therapy.
Main Results:
- Plasmalogens play a dual role in inflammation, with anti-inflammatory signaling pathways and as a source of pro-inflammatory mediators.
- Changes in plasmalogen levels can impact cell membrane properties and inflammatory signaling.
- Plasmalogen analogs of PAF exhibit anti-inflammatory effects.
Conclusions:
- Plasmalogen homeostasis is critical for regulating inflammatory responses.
- Plasmalogen replacement therapy shows promise for treating chronic inflammatory diseases associated with PAF.
- Further research into plasmalogen function could reveal new therapeutic targets.
Keywords:
aginginflammationmetabolic disordersmicroglianeurodegenerative disordersplasmalogenplasmalogen replacement therapyplatelet-activating factor (PAF)More Related Videos
Related Concept Videos
01:22Formation of the Platelet Plug
6.8K
The platelet phase, the second stage of hemostasis, commences around 15-20 seconds after an injury. It follows and overlaps with the vascular phase, during which blood vessels constrict to minimize blood loss.
As the injured blood vessel contracts, endothelial cells undergo contraction, revealing collagen fibers in the basement membrane and underlying connective tissue. Furthermore, the plasma membrane of endothelial cells becomes adhesive, preparing the site for platelet adhesion. Platelets...
As the injured blood vessel contracts, endothelial cells undergo contraction, revealing collagen fibers in the basement membrane and underlying connective tissue. Furthermore, the plasma membrane of endothelial cells becomes adhesive, preparing the site for platelet adhesion. Platelets...
6.8K
01:38Inflammation
54.4K
Overview
54.4K
01:18Structure and Function of Platelets
1.3K
The cell fragments known as platelets are disc-shaped, with an average diameter of about 3 μm and a thickness of roughly 1 μm. They play a crucial role in the body's vascular clotting system, which also involves plasma proteins, blood cells, and blood vessel tissues.
Platelets are continually replenished, circulating in the bloodstream for 9-12 days before being removed by phagocytes, primarily in the spleen. A microliter of circulating blood contains between 150,000 and 450,000...
Platelets are continually replenished, circulating in the bloodstream for 9-12 days before being removed by phagocytes, primarily in the spleen. A microliter of circulating blood contains between 150,000 and 450,000...
1.3K
01:16Clot Retraction and Fibrinolysis
6.7K
After a fibrin clot is formed, the next step is clot retraction, a vital process facilitated by platelet contractile proteins, such as actin and myosin. These proteins pull the fibrin strands closer together and condense the clot. This action reduces the size of the clot, creating a smaller, denser structure that effectively seals off the damaged vessel. Clot retraction consolidates the clot and helps with wound healing by bringing the edges of the damaged blood vessel closer together.
6.7K
01:20Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
597
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
597
01:30Anticoagulant Drugs: Low-Molecular-Weight Heparins
835
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
835